UK feasibility trial finds psilocybin therapy safe for resistant depression
A 2026 feasibility study delivering psilocybin-assisted therapy within the NHS reported high adherence and no safety concerns, raising questions about patient reach, treatment settings and service standards.
A feasibility trial delivering psilocybin-assisted therapy for treatment-resistant depression within the UK health service reported encouraging adherence and safety. The study, authored by L. Galindo, A. Ragnhildstveit and B.J.G. Illingworth and published in Nature Medicine in 2026, enrolled adults whose depression had not responded to conventional treatments and provided the psychedelic intervention under NHS supervision.
Study design and participant pathway
The investigation was structured as a pilot implementation within routine NHS care, aiming to assess whether the complex logistics of psilocybin therapy could be integrated into existing mental-health services. Participants received a preparatory counselling session, a supervised psilocybin dosing appointment, and follow-up integration meetings. The authors note that the trial was publicly and commercially funded, and that L. Galindo serves as principal investigator for several psychedelic-focused clinical programmes.
Safety and adherence outcomes
According to the report, all participants completed the treatment protocol, indicating strong adherence to the scheduled sessions. No serious adverse events were recorded, and the safety monitoring procedures employed by the NHS team appeared sufficient to manage any transient psychological effects. The authors describe the safety profile as "encouraging," suggesting that the controlled environment mitigated the risks historically associated with psychedelic use.
Implications for NHS delivery
The positive feasibility signals open a series of practical questions. First, the authors ask who is most likely to access such therapy when it becomes widely available, noting potential disparities highlighted in earlier work on racial and ethnic health outcomes (Ward et al., 2023). Second, the location of treatment-whether in specialised clinics or broader community settings-remains unresolved. Finally, the study calls for the development of clear clinical standards, training pathways for therapists, and regulatory frameworks to sustain psilocybin-assisted care within the public health system.
The trial adds to a growing body of literature that includes recent investigations of psychedelic therapies for mood disorders (e.g., Hughes & Garcia-Romeu, 2024; Goodwin et al., 2025). While the current work does not provide efficacy data, its demonstration of operational viability is a crucial step toward larger randomized controlled trials that could inform policy decisions.
Future research will need to address scalability, cost-effectiveness, and long-term outcomes, as well as the ethical considerations of expanding access to a substance with a complex cultural history. The authors conclude that the feasibility findings justify further investment in implementation science to bridge the gap between experimental protocols and everyday clinical practice.
The article’s ethics declaration notes that competing interests are limited to L. Galindo’s leadership of publicly and commercially funded psychedelic trials, underscoring the importance of transparency as the field moves toward mainstream adoption.
